REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 8th, 2008 • New Leaf Ventures II, L.P. • Electromedical & electrotherapeutic apparatus • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 31st day of July, 2008 by and among World Heart Corporation, a Canadian corporation (the “Company”), World Heart Inc. (“WHI”), ABIOMED, Inc. (“Abiomed”) and those Investors (as defined below) party as “Investors” to that certain Recapitalization Agreement among the Company, WHI, Abiomed and such Investors (as amended on July 31, 2008, the “Recapitalization Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Recapitalization Agreement unless otherwise defined herein.
RECAPITALIZATION AGREEMENTRecapitalization Agreement • August 8th, 2008 • New Leaf Ventures II, L.P. • Electromedical & electrotherapeutic apparatus • New York
RECAPITALIZATION AGREEMENT, made this 20th day of June, 2008 (this “Agreement”), among World Heart Corporation (the “Company”), World Heart Inc. (“WHI”), ABIOMED, Inc. (“Abiomed”), Venrock Partners V, L.P., Venrock Associates V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, “Venrock”), Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P., Special Situations Private Equity Fund, L.P. and Special Situations Life Sciences Fund, L.P. (collectively, “SSF”) and the investors, mutually agreed upon by Venrock and SSF, such approval not to be unreasonably withheld, delayed or conditioned, who become party hereto after the date of this Agreement by executing and delivering a counterpart of the Joinder Agreement attached hereto as Exhibit A. SSF, Venrock and such investors are hereinafter referred to collectively as the “Investors” and individually as an “Investor”.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GAgreement Regarding Joint Filing of Schedule 13g • February 13th, 2020 • New Leaf Ventures II, L.P. • Surgical & medical instruments & apparatus
The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GJoint Filing Agreement • February 13th, 2020 • New Leaf Ventures II, L.P. • Pharmaceutical preparations
The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GJoint Filing Agreement • February 13th, 2019 • New Leaf Ventures II, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Principia Biopharma Inc.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GAgreement Regarding Joint Filing of Schedule 13g • February 13th, 2019 • New Leaf Ventures II, L.P. • Surgical & medical instruments & apparatus
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Neuronetics, Inc.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GJoint Filing Agreement • February 10th, 2021 • New Leaf Ventures II, L.P. • Surgical & medical instruments & apparatus
The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.
Amendment No. 1 to the Recapitalization AgreementRecapitalization Agreement • August 8th, 2008 • New Leaf Ventures II, L.P. • Electromedical & electrotherapeutic apparatus
This Amendment No. 1 to the Recapitalization Agreement is dated as of July 31, 2008 (this “Amendment No. 1”), by and among (i) World Heart Corporation (the “Company”), (ii) World Heart Inc. (“WHI”), (iii) ABIOMED, Inc. (“Abiomed”), (iv) Venrock Partners V, L.P., Venrock Associates V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, “Venrock”), (v) Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P., Special Situations Private Equity Fund, L.P. and Special Situations Life Sciences Fund, L.P. (collectively, “SSF”) and (vi) New Leaf Ventures II, L.P. (“New Leaf”). Capitalized terms used herein and not otherwise defined have the meanings given them in the Recapitalization Agreement.
